FDA's Complete Response Letter declining approval of MDMA-assisted therapy, citing concerns about blinding methodology and expectancy effects. Authoritative regulatory decision on landmark psychedelic research.
Complete Response Letter for NDA 215455, MDMA-assisted therapy for PTSD (August 2024)